Over the past 10 years, circulating tumor cells (CTC) and circulating tumor DNA (ctDNA)
have received enormous attention as new biomarkers and subjects of translational research …

Colorectal cancer has served as a genetic and biological paradigm for the evolution of solid
tumors, and these insights have illuminated early detection, risk stratification, prevention …

Minimally invasive approaches to detect residual disease after surgery are needed to
identify patients with cancer who are at risk for metastatic relapse. Circulating tumour DNA …

There exists a tremendous opportunity in identifying and determining the appropriate
predictive and prognostic biomarker (s) for risk stratification of patients with colorectal …

PURPOSE Pembrolizumab significantly improves clinical outcomes in advanced/metastatic
microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) solid tumors but is …

Purpose: Sensitive methods for risk stratification, monitoring therapeutic efficacy, and early
relapse detection may have a major impact on treatment decisions and patient management …

The continuous improvement in cancer care over the past decade has led to a gradual
decrease in cancer-related deaths. This is largely attributed to improved treatment and …

Sporadic colorectal cancer has traditionally been viewed as a malignancy of older
individuals. However, as the global prevalence of the disease diagnosed in younger …

Colorectal cancer (CRC) is one of the most prevalent and deadly cancers worldwide.
Despite recent improvements in treatment and prevention, most of the current therapeutic …

PURPOSE Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to
detect molecular residual disease (MRD) has the potential to dramatically affect cancer …